Spero Therapeutics Appoints David Melnick as Chief Medical Officer
January 04, 2018 at 12:30 pm
Share
Spero Therapeutics, Inc. announced the appointment of David Melnick as Chief Medical Officer to oversee Spero's clinical development and regulatory strategy. Dr. Melnick brings significant clinical experience to Spero with 18 years in anti infective drug development including seven successful anti-infective drug approvals. Prior to joining Spero Therapeutics, Dr. Melnick served as Vice President of Clinical Development for Anti Infectives at Allergan since 2015. In that capacity, he oversaw the development and regulatory approval of Teflaro, Avycaz, and Dalvance in the United States. Prior to Allergan, Dr. Melnick served fifteen years at AstraZeneca in various levels of increasing responsibility, most recently as Vice President of Clinical Development for Anti-Infectives. In that capacity, he oversaw the late stage clinical development of Merrem, Teflaro, and Avycaz. In addition, he served as the acting Vice President for early development at AstraZeneca.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
SPERO THERAPEUTICS, INC. 
